Cargando…

Artificial intelligence in pancreatic cancer

Pancreatic cancer is the deadliest disease, with a five-year overall survival rate of just 11%. The pancreatic cancer patients diagnosed with early screening have a median overall survival of nearly ten years, compared with 1.5 years for those not diagnosed with early screening. Therefore, early dia...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Bowen, Huang, Haoran, Zhang, Shuting, Zhang, Dingyue, Shi, Qingya, Liu, Jianzhou, Guo, Junchao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576619/
https://www.ncbi.nlm.nih.gov/pubmed/36276650
http://dx.doi.org/10.7150/thno.77949
_version_ 1784811571758759936
author Huang, Bowen
Huang, Haoran
Zhang, Shuting
Zhang, Dingyue
Shi, Qingya
Liu, Jianzhou
Guo, Junchao
author_facet Huang, Bowen
Huang, Haoran
Zhang, Shuting
Zhang, Dingyue
Shi, Qingya
Liu, Jianzhou
Guo, Junchao
author_sort Huang, Bowen
collection PubMed
description Pancreatic cancer is the deadliest disease, with a five-year overall survival rate of just 11%. The pancreatic cancer patients diagnosed with early screening have a median overall survival of nearly ten years, compared with 1.5 years for those not diagnosed with early screening. Therefore, early diagnosis and early treatment of pancreatic cancer are particularly critical. However, as a rare disease, the general screening cost of pancreatic cancer is high, the accuracy of existing tumor markers is not enough, and the efficacy of treatment methods is not exact. In terms of early diagnosis, artificial intelligence technology can quickly locate high-risk groups through medical images, pathological examination, biomarkers, and other aspects, then screening pancreatic cancer lesions early. At the same time, the artificial intelligence algorithm can also be used to predict the survival time, recurrence risk, metastasis, and therapy response which could affect the prognosis. In addition, artificial intelligence is widely used in pancreatic cancer health records, estimating medical imaging parameters, developing computer-aided diagnosis systems, etc. Advances in AI applications for pancreatic cancer will require a concerted effort among clinicians, basic scientists, statisticians, and engineers. Although it has some limitations, it will play an essential role in overcoming pancreatic cancer in the foreseeable future due to its mighty computing power.
format Online
Article
Text
id pubmed-9576619
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Ivyspring International Publisher
record_format MEDLINE/PubMed
spelling pubmed-95766192022-10-20 Artificial intelligence in pancreatic cancer Huang, Bowen Huang, Haoran Zhang, Shuting Zhang, Dingyue Shi, Qingya Liu, Jianzhou Guo, Junchao Theranostics Review Pancreatic cancer is the deadliest disease, with a five-year overall survival rate of just 11%. The pancreatic cancer patients diagnosed with early screening have a median overall survival of nearly ten years, compared with 1.5 years for those not diagnosed with early screening. Therefore, early diagnosis and early treatment of pancreatic cancer are particularly critical. However, as a rare disease, the general screening cost of pancreatic cancer is high, the accuracy of existing tumor markers is not enough, and the efficacy of treatment methods is not exact. In terms of early diagnosis, artificial intelligence technology can quickly locate high-risk groups through medical images, pathological examination, biomarkers, and other aspects, then screening pancreatic cancer lesions early. At the same time, the artificial intelligence algorithm can also be used to predict the survival time, recurrence risk, metastasis, and therapy response which could affect the prognosis. In addition, artificial intelligence is widely used in pancreatic cancer health records, estimating medical imaging parameters, developing computer-aided diagnosis systems, etc. Advances in AI applications for pancreatic cancer will require a concerted effort among clinicians, basic scientists, statisticians, and engineers. Although it has some limitations, it will play an essential role in overcoming pancreatic cancer in the foreseeable future due to its mighty computing power. Ivyspring International Publisher 2022-10-03 /pmc/articles/PMC9576619/ /pubmed/36276650 http://dx.doi.org/10.7150/thno.77949 Text en © The author(s) https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.
spellingShingle Review
Huang, Bowen
Huang, Haoran
Zhang, Shuting
Zhang, Dingyue
Shi, Qingya
Liu, Jianzhou
Guo, Junchao
Artificial intelligence in pancreatic cancer
title Artificial intelligence in pancreatic cancer
title_full Artificial intelligence in pancreatic cancer
title_fullStr Artificial intelligence in pancreatic cancer
title_full_unstemmed Artificial intelligence in pancreatic cancer
title_short Artificial intelligence in pancreatic cancer
title_sort artificial intelligence in pancreatic cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9576619/
https://www.ncbi.nlm.nih.gov/pubmed/36276650
http://dx.doi.org/10.7150/thno.77949
work_keys_str_mv AT huangbowen artificialintelligenceinpancreaticcancer
AT huanghaoran artificialintelligenceinpancreaticcancer
AT zhangshuting artificialintelligenceinpancreaticcancer
AT zhangdingyue artificialintelligenceinpancreaticcancer
AT shiqingya artificialintelligenceinpancreaticcancer
AT liujianzhou artificialintelligenceinpancreaticcancer
AT guojunchao artificialintelligenceinpancreaticcancer